Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study-Reference-Cited by-同舟云学术

Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study

Published:2021-02-18 Issue:9 Volume:27 Page:2515-2522
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Kagawa Yoshinori,Elez Elena,García-Foncillas Jesús,Bando Hideaki^ORCID,Taniguchi Hiroya^ORCID,Vivancos Ana,Akagi Kiwamu,García Ariadna,Denda Tadamichi,Ros Javier,Nishina Tomohiro,Baraibar Iosune^ORCID,Komatsu Yoshito,Ciardiello Davide^ORCID,Oki Eiji^ORCID,Kudo Toshihiro,Kato Takeshi^ORCID,Yamanaka Takeharu,Tabernero Josep^ORCID,Yoshino Takayuki

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study;Nature Communications;2024-08-23

2. Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial;Annals of Oncology;2024-08

3. Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study;Journal of Cancer Research and Clinical Oncology;2024-07-27

4. Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors;Clinical Cancer Research;2024-07-12

5. Liquid biopsy as a tool for KRAS/NRAS/BRAF baseline testing in metastatic colorectal cancer;Clinics and Research in Hepatology and Gastroenterology;2024-07